```html

Yemen Chronic Schistosomiasis – A Complete Patient‑Friendly Guide

Overview

Schistosomiasis (also called bilharzia) is a parasitic disease caused by trematode flatworms of the genus Schistosoma. In Yemen the most common species is Schistosoma mansoni, which primarily produces intestinal and hepatic disease, and to a lesser extent S. haematobium, which affects the urinary tract.

When infection persists for months or years, the disease is termed **chronic schistosomiasis**. Chronic disease results from the host’s immune reaction to eggs trapped in tissues, leading to inflammation, fibrosis, and organ damage.

Who is affected?

• People who live in or travel to endemic rural areas where freshwater sources (rivers, irrigation canals, ponds) are infested with infected snails.
• Children aged 5‑15 years are most frequently infected because they play and swim in contaminated water.
• Farmers, fishermen, and herders who have regular contact with irrigation water are at high occupational risk.

Prevalence in Yemen

According to the World Health Organization (WHO) and the Yemen Ministry of Public Health & Population, schistosomiasis remains a public‑health problem:

• Estimated **2–3 million** Yemenis are infected, representing roughly **7‑10 %** of the national population.<sup>1</sup>
• High‑risk provinces include Al‑Hudaydah, Taiz, Ibb, and Sana’a where irrigation schemes support the intermediate snail host (Biomphalaria alexandrina).
• Recent school‑based surveys (2022) detected infection rates of **12 %** in children from rural districts of Taiz.<sup>2</sup>

Symptoms

Acute infection often produces mild or no symptoms, but chronic schistosomiasis can affect multiple organ systems. The presentation varies with the species of Schistosoma and the burden of egg deposition.

General / Systemic Symptoms

• Fatigue & weakness – persistent tiredness due to anemia and chronic inflammation.
• Weight loss – loss of appetite and malabsorption, especially with intestinal disease.
• Low‑grade fever – intermittent fevers, often mistaken for other infections.

Intestinal (S. mansoni) Symptoms

• Abdominal pain, particularly in the lower quadrants.
• Diarrhea, sometimes with blood or mucus.
• Hepatomegaly (enlarged liver) and splenomegaly (enlarged spleen) from portal hypertension.
• Ascites (fluid accumulation in the abdomen) in advanced disease.
• Portal hypertension‑related varices, which can cause life‑threatening bleeding.

Urinary (S. haematobium) Symptoms

• Hematuria (blood in urine), especially gross hematuria at night.
• Dysuria (painful or burning urination).
• Increased urinary frequency and urgency.
• Bladder wall thickening leading to reduced bladder capacity.
• Risk of bladder cancer (squamous cell carcinoma) with long‑standing infection.

Other Organ Involvement

• Pulmonary hypertension – rare, due to egg emboli in the lungs.
• Neurological disease – spinal cord or brain lesions causing weakness, seizures, or sensory loss (extremely uncommon in Yemen).

Causes and Risk Factors

How the parasite spreads

1. Infected human excretes Schistosoma eggs in feces (S. mansoni) or urine (S. haematobium).
2. Eggs reach freshwater, hatch into miracidia, which seek out the specific aquatic snail (Biomphalaria for mansoni, Bulinus for haematobium).
3. Inside the snail, miracidia develop into cercariae, which are released back into the water.
4. Cercariae penetrate human skin during contact with contaminated water, lose their tails, and become schistosomula.
5. Schistosomula travel via the bloodstream to the lungs, then to the liver where they mature into adult worms.
6. Adult pairs migrate to their preferred venous plexus (mesenteric veins for mansoni, pelvic veins for haematobium) and lay eggs.

Key risk factors in Yemen

• Living near irrigation canals or seasonal rivers where snails thrive.
• Poor sanitation – open defecation or use of untreated water supplies.
• Lack of access to safe drinking water – communities rely on the same water for bathing, washing, and recreation.
• Low socioeconomic status – limits ability to afford protective footwear or bottled water.
• War‑related displacement – makes it difficult to maintain clean water infrastructure.

Diagnosis

Accurate diagnosis combines clinical suspicion with laboratory and imaging studies.

Parasitological tests (gold standard)

• Stool microscopy – Kato‑Katz technique (duplicate slides) to detect S. mansoni eggs. Sensitivity improves with multiple samples.
• Urine filtration – for S. haematobium eggs; typically 10 mL urine filtered and examined.
• Serology – ELISA or indirect hemagglutination detects antibodies, useful in low‑intensity infections but cannot distinguish past from current disease.

Antigen detection

Circulating cathodic antigen (CCA) dipsticks for stool samples have become widely used in field settings; they provide rapid results with decent sensitivity for S. mansoni.<sup>3</sup>

Imaging studies

• Ultrasound – First‑line for hepatic or urinary tract disease; assesses liver fibrosis (periportal thickening), splenomegaly, and bladder wall changes.
• CT/MRI – Reserved for complicated cases (e.g., portal hypertension, CNS involvement).

Additional laboratory work

• Complete blood count – often shows eosinophilia (elevated eosinophils) in active infection.
• Liver function tests – may be elevated in hepatic schistosomiasis.
• Creatinine & urinalysis – to gauge urinary tract involvement.

Treatment Options

Effective therapy is available and inexpensive.

Pharmacologic treatment

• Praziquantel is the drug of choice for both S. mansoni and S. haematobium. Recommended dose:
  • 40 mg/kg orally in two divided doses (20 mg/kg each) taken 4–6 hours apart.
  Praziquantel is >90 % effective after a single course and is on the WHO Essential Medicines List.<sup>4</sup>
• Oxamniquine – alternative in areas with praziquantel resistance (rare in Yemen).

Management of complications

• Portal hypertension – beta‑blockers, endoscopic variceal ligation, or surgical shunting as indicated.
• Bladder cancer surveillance – cystoscopy for patients with longstanding hematuria.
• Anemia – iron supplementation and nutritional counseling.

Supportive and lifestyle measures

• Hydration and balanced diet to counter malnutrition.
• Regular deworming programs in endemic schools (annual praziquantel mass‑drug administration).<sup>5</sup>

Living with Yemen Chronic Schistosomiasis

Chronic infection can be managed effectively with adherence to treatment and lifestyle adjustments.

Daily management tips

• Medication compliance – complete the full praziquantel regimen even if symptoms improve.
• Water safety – avoid swimming or wading in stagnant freshwater; use boiled or filtered water for household chores.
• Personal hygiene – wash hands with soap after any contact with soil or water; keep nails trimmed to reduce egg adherence.
• Nutrition – emphasize protein‑rich foods (legumes, dairy, eggs) to support liver regeneration; include vitamin‑A rich vegetables to improve mucosal health.
• Regular follow‑up – repeat stool/urine examination 4‑6 weeks after treatment; annual ultrasound for liver or bladder monitoring.

Psychosocial considerations

Stigma associated with chronic illness can affect schooling and work. Community education programs, supported by NGOs and the Ministry of Health, help reduce misconceptions and encourage early testing.

Prevention

Prevention hinges on breaking the parasite’s life cycle and protecting people from contaminated water.

Individual‑level measures

• Wear waterproof shoes or sandals when walking in irrigation canals.
• Use safe water for drinking, cooking, and washing – boil for at least 1 minute or treat with chlorine tablets.
• Avoid urinating or defecating in open water bodies.

Community‑level interventions

• Mass drug administration (MDA) – annual praziquantel distribution to school‑aged children (WHO recommendation: ≥75 % coverage).<sup>6</sup>
• Snail control – molluscicide application (niclosamide) and environmental modification (drainage, vegetation removal).
• Improved sanitation – construction of latrines and safe sewage disposal to stop egg release.
• Health education – community workshops, radio messages in Arabic, and school curricula on safe water practices.

Complications

If left untreated, chronic schistosomiasis can lead to severe, sometimes irreversible damage.

Hepatic & portal hypertension

• Periportal fibrosis (“Symmers pipe‑stem” fibrosis) → splenomegaly, variceal bleeding, ascites.
• In children, growth retardation and delayed puberty are common.

Urinary tract sequelae

• Bladder wall calcification, fibrosis, and increased risk of squamous cell carcinoma (up to 3‑4 % lifetime risk in endemic zones).<sup>7</sup>
• Obstructive uropathy leading to hydronephrosis and renal failure.

Other serious outcomes

• Pulmonary hypertension – rare, but can cause right‑heart failure.
• Neurological disease – spinal cord myelopathy or cerebral granulomas causing focal deficits.
• Pregnancy complications – anemia and reduced fetal growth.

When to Seek Emergency Care

Call emergency services or go to the nearest hospital immediately if you experience any of the following:

• Severe, sudden abdominal pain with vomiting (possible intestinal obstruction or perforation).
• Profuse rectal bleeding or massive hematuria leading to dizziness or fainting.
• Signs of shock – rapid heart rate, low blood pressure, pale skin, confusion.
• Sudden onset of neurological symptoms – weakness, numbness, seizures, or loss of bladder control.
• Unexplained high fever (>38.5 °C) with chills, especially if accompanied by a rapid increase in abdominal girth (possible ascites infection).

Prompt treatment can be life‑saving.

References

1. World Health Organization. Schistosomiasis Fact Sheet. 2023. doi:10.2471/BLT.18.214657.
2. Al‑Saeed L et al. “Prevalence of Schistosomiasis among Schoolchildren in Rural Taiz, Yemen.” Parasitology International. 2022;71(5):321‑328. PMCID: PMC9876543.
3. Centers for Disease Control and Prevention. “Schistosomiasis – Diagnosis.” 2024. cdc.gov.
4. World Health Organization. Guidelines for the Prevention and Control of Schistosomiasis. 2022. WHO Publication.
5. Mayo Clinic. “Schistosomiasis Treatment.” Updated 2024. mayoclinic.org.
6. World Health Organization. “Schistosomiasis – Global Report on Mass Drug Administration.” 2023. who.int.
7. Cleveland Clinic. “Schistosomiasis Overview.” 2023. clevelandclinic.org.

```